Sponsor Directory

AstraZeneca clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1904

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Respiratory Syncytial Virus Infections
Interventions: MEDI8897, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 0 Years to 1 Year
Enrollment: 3,012 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 66
States / cities: Birmingham, Alabama • Fort Defiance, Arizona • Fayetteville, Arkansas + 59 more

Conditions: Urothelial Carcinoma
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 58
States / cities: Little Rock, Arkansas • Glendale, California • Los Angeles, California + 54 more

Conditions: Advanced Malignancies
Interventions: AZD7648, PLD; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: New Haven, Connecticut • Houston, Texas

Conditions: COVID-19, SARS-CoV-2
Interventions: AZD1222, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 32,450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 78
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 66 more

Conditions: Non-small Cell Lung Cancer
Interventions: Ramucirumab, Necitumumab, Osimertinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma
Interventions: MEDI3506, Placebo; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 9
States / cities: Bakersfield, California • Los Angeles, California • Newport Beach, California + 6 more

Conditions: Heart Failure
Interventions: Best practice alert for the notification of patient HFrEF and recommended evidence-based medical therapies (NO drugs are being administered in this trial); Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 1,012 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Solid Tumour
Interventions: Capivasertib, Midazolam; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Aurora, Colorado • Durham, North Carolina • Cleveland, Ohio + 2 more

Conditions: Lung Cancer, Gastro-intestinal Cancer
Interventions: Durvalumab, Adagrasib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Solid Tumors
Interventions: DS-8201a (DP1), DS-8201a (DP2), DS-8201a (DP); Drug
Lead sponsor: Daiichi Sankyo Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 8
States / cities: San Diego, California • Jacksonville, Florida • Louisville, Kentucky + 5 more

Conditions: Breast Neoplasms
Interventions: Olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2022
U.S. locations: 2
States / cities: West Hollywood, California • Boston, Massachusetts

Conditions: Non-alcoholic Steatohepatitis (NASH)
Interventions: AZD2693, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 16
States / cities: Chula Vista, California • La Mesa, California • Montclair, California + 11 more

About this AstraZeneca sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AstraZeneca is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AstraZeneca trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AstraZeneca clinical trials

Filter and sort this sponsor

Live official records

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)

Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma

A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma

PRagmatic Trial Of Messaging to Providers About Treatment of Heart Failure in the Inpatient Setting

A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours

A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer

A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients

About this AstraZeneca sponsor directory page